Huaxi Hospital
12
2
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.4% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
Role: collaborator
Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics
Role: collaborator
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
Role: collaborator
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
Role: collaborator
Interventional Ablation for Early-stage Lung Cancer
Role: collaborator
Silicone Oil Tamponade for Vitrectomy of Hypermyopic Foveoschisis.
Role: collaborator
Quality of Life in Chinese Working and School Age Population With MDD
Role: collaborator
Autologous Adipose Stem Cell Assisted Skin Graft
Role: collaborator
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Role: collaborator
Safety and Efficacy of Simultaneous or Staged Surgery on Complicated Hepatolithiasis
Role: collaborator
Combined Treatment of RFA and Sorafenib on Recurrent HCC
Role: collaborator
Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p
Role: collaborator
All 12 trials loaded